Synthon Hispania, S.L. (primary, secondary packaging, quality control, batch release)
UkraineAll drugs from this manufacturer
-
The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), advanced renal cell carcinoma, as well as unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs.
Dosage form: tablets
Active substance Dosage everolimus 2.5 mg ATC: L01EG02
-
The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), advanced renal cell carcinoma, as well as unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs.
Dosage form: tablets
Active substance Dosage everolimus 5 mg ATC: L01EG02
-
The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), advanced renal cell carcinoma, as well as unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs.
Dosage form: tablets
Active substance Dosage everolimus 10 mg ATC: L01EG02